COVID-19 Research Paper Volume 13, Issue 18 pp 21866—21902
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Figure 4. Network meta-analyses of the relative efficacy and safety of medications in non-severe COVID-19 patients. (A) The ratio of virological cure. (B) All-cause mortality. (C) The ratio of treatment-emergent adverse events. Abbreviations: COVID-19: coronavirus disease 2019; OR: odds ratio; CI: confidence interval; PL: peginterferon lambda; LDI: low dosage ivermectin; LPV/r: lopinavir–ritonavir; AZM: azithromycin; HDVD: high-dose vitamin D; HDIVZn: high-dose intravenous zinc; LCP: low dosage CT-P59; HCP: high dosage CT-P59; CPC: CT-P59 combined; HCQ: hydroxychloroquine; LDB: low dosage bamlanivimab; MDB: moderate dosage bamlanivimab; HDB: high dosage bamlanivimab; LS: low dosage sarilumab; HS: high dosage sarilumab; NPF: novel probiotic formulation; CP: convalescent plasma; ALA: α-Lipoic acid; IFN-β: interferon beta; IG: immunoglobulin gamma.